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Objective: We present prenatal diagnosis and molecular genetic analysis of mosaic trisomy 17 and a
review of the literature of mosaic trisomy 17 at amniocentesis.
Materials and Methods: A 42-year-old woman underwent amniocentesis at 17 weeks of gestation
because of advanced maternal age, which revealed a karyotype of 47,XX,þ17[4]/46,XX[17]. Prenatal ul-
trasound ﬁndings were unremarkable. She underwent repeat amniocentesis at 20 weeks of gestation.
Interphase ﬂuorescence in situ hybridization (FISH), array comparative genomic hybridization, and
quantitative ﬂuorescent polymerase chain reaction assays were applied to uncultured amniocytes.
Conventional cytogenetic analysis was applied to cultured amniocytes and cord blood. Interphase FISH
was applied to uncultured urinary cells postnatally.
Results: At repeat amniocentesis, molecular genetic analysis of uncultured amniocytes revealed no
genomic imbalance in array comparative genomic hybridization, no uniparental disomy 17 in quanti-
tative ﬂuorescent polymerase chain reaction, and 4.7% (5/105 cells) mosaic trisomy 17 in interphase FISH
analysis. Conventional cytogenetic analysis of cultured amniocytes revealed a karyotype of 46,XX (17/17
colonies). A phenotypically normal baby was delivered at 38 weeks of gestation. The cord blood had a
karyotype of 46,XX. Interphase FISH analysis of uncultured urinary cells revealed 5.6% (5/90 cells) mosaic
trisomy 17. The neonate manifested normal growth and psychomotor development during follow-ups.
Conclusion: Low-level mosaicism for trisomy 17 detected by amniocentesis without ultrasound abnor-
mality can be associated with a favorable outcome. Molecular genetic analysis of uncultured amniocytes
at repeat amniocentesis is useful for genetic counseling. A review of the literature shows a correlation
between an adverse fetal outcome and a higher trisomy 17 mosaicism level at amniocentesis associated
with ultrasound abnormality.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).s and Gynecology, Mackay
Road, Taipei, Taiwan.
).
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We previously reported molecular genetic analysis of prenatally
detected mosaic trisomy 2 [1,2], mosaic trisomy 7 [3], mosaic tri-
somy 12 [4], mosaic trisomy 15 [5], and mosaic trisomy 21 [6] by
interphase ﬂuorescence in situ hybridization (FISH), array
comparative genomic hybridization (aCGH), and quantitativeby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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cultured amniocytes. Herein, we present an additional case of
mosaic trisomy 17 using the same methods. Our case demonstrates
that low-level mosaicism for trisomy 17 detected by amniocentesis
can be associated with a favorable outcome. Molecular genetic
analysis of uncultured amniocytes at repeat amniocentesis is useful
for genetic counseling.
Materials and methods
Clinical description
A 42-year-old, gravida 2, para 1, woman underwent amniocen-
tesis at 17 weeks of gestation because of advanced maternal age.
Amniocentesis revealed a karyotype of 47,XX,þ17[4]/46,XX[17].
Among 21 colonies of cultured amniocytes, four colonies had the
karyotype of 47,XX,þ17, whereas the other 17 colonies had a normal
karyotype of 46,XX. She was referred to the hospital for genetic
counseling. The parental karyotypes were normal, and prenatal
ultrasound ﬁndings were unremarkable. She underwent repeat
amniocentesis at 20 weeks of gestation. Interphase FISH, aCGH, and
QF-PCR assays were applied to uncultured amniocytes, and con-
ventional cytogenetic analysis was applied to cultured amniocytes
and cord blood. Interphase FISH was applied to uncultured urinary
cells postnatally. A phenotypically normal 2748 g female baby was
delivered at 38 weeks of gestation. She showed normal growth and
psychomotor development during follow-ups at 11 months of age.
aCGH
Whole-genome aCGH on the DNA extracted from uncultured
amniocytes derived from 10 mL of amniotic ﬂuid was performed
using NimbleGen ISCA Plus Cytogenetic Array (Roche NimbleGen,
Madison,WI, USA). The NimbleGen ISCA Plus Cytogenetic Array has
630,000 probes and a median resolution of 15e20 kb across the
entire genome.
QF-PCR
QF-PCR analysis was performed on the DNA extracted from
uncultured amniocytes and parental bloods. Brieﬂy, primers spe-
ciﬁcally ﬂanking short tandem repeat markers on chromosome 17
region, such as D17S2180 (17q21), D17S1290 (17q23.1), and
D17S1304 (17q25.1), were applied to undertake polymorphic
marker analysis to exclude uniparental disomy 17 (UPD 17) and
determine the parental origin of genomic imbalance if detected.
FISH
Interphase FISH analysis was performed on 105 uncultured
amniocytes prenatally and 90 uncultured urinary cells postnatally
using a 17q25.3-speciﬁc bacterial artiﬁcial chromosome probe
RP11-196O11 encompassing 80,858,759e81,021,949 (University of
California, Santa Cruz hg19) (spectrum green, ﬂuorescein isothio-
cyanate) and a 17p13.3-speciﬁc bacterial artiﬁcial chromosome
probe RP11-74E22 encompassing 2,586,599e2,588,382 (University
of California, Santa Cruz hg19) (spectrum red, Texas Red), according
to the standard FISH protocol.
Conventional cytogenetic analysis
Routine cytogenetic analysis by G-banding techniques at 550
bands of resolution was performed on cultured amniocytes at
repeat amniocentesis and cord blood after birth.Results
At repeat amniocentesis, conventional cytogenetic analysis of
cultured amniocytes revealed a karyotype of 46,XX in all the 17
colonies of cultured amniocytes, and molecular genetic analysis of
uncultured amniocytes revealed no genomic imbalance in aCGH.
QF-PCR analysis of the DNA extracted from uncultured amniocytes
and parental bloods revealed a biparental allelic pattern for chro-
mosome 17-speciﬁc markers and thus excluded UPD 17 in the fetus.
Interphase FISH analysis of uncultured amniocytes revealed 4.7%
(5/105 cells) mosaic trisomy 17 compared with 2.9% (2/71 cells) in
normal controls. The cord blood had a karyotype of 46,XX (40/
40 cells). Interphase FISH analysis of uncultured urinary cells
revealed 5.6% (5/90 cells) mosaic trisomy 17 comparedwith 1.6% (2/
123 cells) in normal controls.
Discussion
To date, at least 29 cases (including this presentation) of mosaic
trisomy 17 and/or trisomy 17 detected by amniocentesis have been
reported (Table 1) [7e26]. Of these 29 cases, nine (9/29; 31.03%)
[19,21e26] were associated with prominent phenotypic abnor-
malities, suggesting that the malformation risk should be given
consideration in prenatal diagnosis of mosaic trisomy 17 by
amniocentesis. In the nine cases with an apparently abnormal
outcome, the percentage of trisomic cells in cultured amniocytes
(1st tap) varied from 23.6% to 100% (with 7 cases  33.3%, 5 cases
40%, and 4 cases 50%). In the 20 cases with a normal or nearly
normal outcome, the percentage of trisomic cells in cultured
amniocytes (1st tap) varied from 4.3% to 100% (with 19
cases 40.9%, 17 cases 33%, and 14 cases  19.1%). These ﬁndings
indicate a correlation between a higher trisomy 17 mosaicism level
and an adverse fetal outcome. Of interest is that one out of 20 cases
with a normal outcome was associated with 100% trisomy 17 dur-
ing the ﬁrst amniocentesis [11e13]. Butler et al [11] reported a case
of mosaic trisomy 17 with the ﬁrst amniocentesis due to elective
maternal serum a-fetoprotein having trisomy 17 in 26/26 colonies
and the second amniocentesis having trisomy 17 in 71.4% of 21
colonies. This particular case resulted in a normal live-born. Table 1
shows that all 20 cases with a normal outcome were associated
with a normal prenatal ultrasound, whereas all nine cases with an
abnormal outcome were associated with an abnormal prenatal
ultrasound. Therefore, abnormal ultrasound ﬁndings in addition to
a higher trisomy 17 mosaicism level are correlated with an adverse
fetal outcome in cases with mosaic trisomy 17 detected by
amniocentesis. The reported abnormal ultrasound ﬁndings associ-
ated with mosaic trisomy 17 at amniocentesis include intrauterine
growth restriction, hypoplastic cerebellar vermis, cerebellar hypo-
plasia, ventriculomegaly, pleural effusion, congenital heart defects,
nuchal thickening, cystic hygroma, single umbilical artery, and
short long bones. Prenatal diagnosis of mosaic trisomy 17 should
pay special attention to the brain, especially the cerebellum. Table 1
shows that ﬁve of nine cases with fetal abnormalities were asso-
ciated with cerebellar hypoplasia and/or hypoplastic cerebellar
vermis. Table 1 shows a limitation of application of cord blood
sampling for the conﬁrmation of mosaic trisomy 17 detected by
amniocentesis because almost all of the cases with cord blood
analysis revealed a normal karyotype. At least one case in Table 1
was associated with UPD 17 [15]. Therefore, a testing for UPD 17
should be performed in case of mosaic trisomy 17 at amniocentesis.
Table 1 also shows that the male/female sex ratio for fetal mosaic
trisomy 17 is 0.93 (14 males/15 females), indicating no gender bias
in fetal mosaic trisomy 17.
Postnatally detected mosaic trisomy 17 has been reported in
newborns with severe malformations [27,28]. Bullerdiek and
Table 1
Reported cases of mosaic trisomy 17 and/or trisomy 17 detected by amniocentesis.
Authors Cases Indication Amniocentesis Conﬁrmatory studies Outcome & phenotype
Kalousek et al [7]
Case 2 47,XY,þ17/46,XY AMA T17 ¼ 36.8% (19 colonies) Cord blood: T17 ¼ 0%
(100 cells)
Amnion: T17¼ 0% (38 cells)
Chorion & chorionic villi:
T17 ¼ 57.3% (138 cells)
Normal live-born, delivery
at term, 3940 g, normal
growth and development
Wilson et al [8] 47,XX,þ17/46,XX d T17 ¼ 5% (170 cells) Blood: T17 ¼ 0%
Amnion: T17 ¼ 0%
Normal live-born
Hsu et al [13]
Case XV-7
Welborn & Lewis [9] 47,XX,þ17/46,XX d T17 ¼ 6.3% (32 colonies) d Normal live-born
Djalali et al [10] 47,XY,þ17/46,XY AMA T17 ¼ 19.1% (68 cells) Peripheral blood: T17 ¼ 0%
(100 cells)
Normal live-born, delivery
at 38 wk, 3450 g, normal at
age 18 mo
Butler et al [11] 47,XX,þ17/46,XX Elevated MSAFP T17 ¼ 100% (26 colonies)
Retap:
T17 ¼ 71.4% (21 colonies)
Cord blood: T17 ¼ 0%
(30 cells)
No UPD 17
Normal live-born, delivery
at 40 wk, 2948 g, normal at
age 1 y & 4 y 7 mo
Butler [12]
Hsu et al [13]
Case XV-4
Hsu et al [13]
Case XV-2 47,XY,þ17/46,XY d T17 ¼ 6.5% (62 cells) Cord blood: T17 ¼ 0% Normal live-born, normal at
age 10 mo
Case XV-3 47,XY,þ17/46,XY AMA T17 ¼ 10.7% (28 colonies)
Retap:
T17 ¼ 9.1% (22 colonies)
d Normal live-born
Case XV-5 47,XX,þ17/46,XX AMA T17 ¼ 25% (40 cells) Abortion ﬂuid: T17 ¼ 0%
(60 cells)
TOP, normal abortus
Case XV-6 47,XX,þ17/46,XX d T17 ¼ 9.1% (87 cells) Blood: T17 ¼ 0% Normal live-born, normal at
age 1 y
Djalali et al [14]
Case 1 47,XY,þ17/46,XY AMA T17 ¼ 4.3% (94 cells)
Retap:
T17 ¼ 9% (FISH)
Peripheral blood: T17 ¼ 0%
(100 cells)
Normal live-born, delivery
at term, normal at age
30 mo
Case 2 47,XY,þ17/46,XY Anxiety T17 ¼ 9.2% (109 cells) Cord blood: T17 ¼ 0%
(50 cells)
Cord: T17 ¼ 0% (17 cells)
Amnion: T17¼ 0% (48 cells)
Placenta: T17 ¼ 0%
Normal live-born, delivery
at term, normal at age 2 y
Case 3 47,XX,þ17/46,XX AMA T17 ¼ 10.8% (37 cells)
T17 ¼ 24% (25 colonies)
Peripheral blood: T17 ¼ 0%
(30 cells)
Normal live-born, delivery
at term, normal at age 4½ y
Genuardi et al [15]
Case 1 47,XX,þ17/46,XX AMA T17 ¼ 18.6% (70 cells)
Retap at term:
T17 ¼ 0.8% (130 cells)
Cord blood: T17 ¼ 0%
(100 cells)
Placenta: T17 ¼ 1%
(100 cells)
Cord: T17 ¼ 0% (100 cells)
Amnion: T17 ¼ 1%
(100 cells)
Peripheral blood: T17 ¼ 0%
Normal live-born, delivery
at term, 3740 g, normal at
age 2½ y
Case 2 47,XY,þ17/46,XY AMA T17 ¼ 25% (8 colonies)
Retap:
T17 ¼ 30.8% (13 colonies)
Cord blood: T17 ¼ 0%
(100 cells)
Peripheral blood: T17 ¼ 0%
Maternal UPD 17
Normal live-born, delivery
at 38 wk, 3030 g, normal at
age 2 y
Case 3 47,XX,þ17/46,XX Elective T17 ¼ 8% (50 cells)
Retap:
T17 ¼ 4%
Skin: T17 ¼ 5% (100 cells)
Fascia: T17 ¼ 0% (100 cells)
TOP at 21 wk, no major
phenotypic malformations
Lesca et al [16]
Twin 2
47,XY,þ17/46,XY AMA T17 ¼ 14% (50 cells) Cord blood: T17 ¼ 0%
T17 ¼ 0% (200 cells) (FISH)
Placenta: T17 ¼ 0%
Skin ﬁbroblasts: T17 ¼ 96%
(25 cells)
T17¼ 76% (289 cells) (FISH)
Delivery at 33 wk, 1800 g,
borderline facial
dysmorphism, mild
neurological involvement
at age 2½ mo
Nassar et al [17] 47,XX,þ17/46,XX AMA T17 ¼ 21% (14 colonies) Postnatal chromosome
analysis:
T17 ¼ 0%
Normal live-born, delivery
at 38 wk, 3405 g, normal at
age 10 mo
Collado et al [18] 47,XX,þ17/46,XX Down risk ¼ 1/249 T17 ¼ 40.9% (44 cells)
Retap:
T17 ¼ 7.5% (40 cells)
Cord blood: T17 ¼ 0% Normal live-born, delivery
at 36 wk, 2875 g, normal at
age 14 mo
Terhal et al [19] 47,XY,þ17/46,XY Abnormal ultrasound:
IUGR, hypoplasia of
cerebellar vermis
T17 ¼ 67% (60 cells)
Retap:
T17 ¼ 63% (30 cells)
Cord blood: T17 ¼ 0%
(50 cells)
Chorionic villi (CVS):
T17 ¼ 0% (10 cells)
Peripheral blood: T17 ¼ 0%
(50 cells)
Placenta: T17 ¼ 0%
(45 cells)
Abnormal live-born,
delivery at 38 wk, 2210 g,
mental retardation, growth
retardation, peripheral
neuropathy, hypoplastic
cerebellar vermis, zonular
cataract, & body
asymmetry at age 7 y
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Table 1 (continued )
Authors Cases Indication Amniocentesis Conﬁrmatory studies Outcome & phenotype
Skin ﬁbroblasts (left leg):
T17 ¼ 69% (16 cells)
T17 ¼ 22% (50 cells) (FISH)
Skin ﬁbroblasts (right leg):
T17 ¼ 25% (32 cells)
T17 ¼ 8% (50 cells) (FISH)
No UPD 17, maternal origin
of T17
Abrams et al [20] 47,XY,þ17/46,XY AMA T17 ¼ two colonies in 2/6
cultures (total 37 cells)
d Normal live-born, delivery
at term, 6 pounds & 6
ounces, normal at age 2 y
Utermann et al [21]
Patient 1 47,XX,þ17/46,XX AMA, abnormal ultrasound,
Down risk ¼ 1/156, T17
at CVS
T17 ¼ 30% (10 colonies)
T17 ¼ 8.4% (36 cells, FISH)
CVS: T17 ¼ 0% (20 cells)
(STC)
T17 ¼ 100% (17 cells) (LTC)
Placenta: T17 ¼ 23%
(9 cells) (STC)
Placenta: T17 ¼ 70%
(115 cells) (FISH)
T17 ¼ 71% (100 cells) (FISH)
T17 ¼ 55% (100 cells) (FISH)
No UPD 17, maternal origin
of T17
Abnormal ultrasound:
IUGR, VSD, cerebellar
hypoplasia, clitoral
hypertrophy, TOP, facial
dysmorphism, abnormal
fetus
Patient 3 47,XX,þ17/46,XX Abnormal ultrasound:
nuchal thickening
T17 ¼ 40% (20 colonies) Placenta: T17 ¼ 22%
(100 cells) (FISH)
Blood: T17 ¼ 0% (100 cells)
Skin ﬁbroblasts (ﬁnger):
T17 ¼ 70% (20 cells)
Skin ﬁbroblasts (toe):
T17 ¼ 0% (100 cells) (FISH)
Skin ﬁbroblasts (hip):
T17 ¼ 0% (100 cells) (FISH)
Buccal smear:
T17 ¼ 0% (400 cells) (FISH)
T17 ¼ 0.75% (400 cells)
(FISH)
No UPD 17, paternal origin
of T17
Additional abnormal
ultrasound of IUGR, single
umbilical artery, foot
position abnormality,
delivery at 37 wk, 1959 g,
facial dysmorphism,
postaxial polydactyly of left
hand & feet, congenital hip
dislocation, inguinal hernia,
mild kyphoscoliosis at age
18 mo
Patient 4 47,XY,þ17/46,XY Abnormal ultrasound:
IUGR
T17 ¼ 33.3% (24 colonies)
T17 ¼ 69.4% (72 cells, FISH)
T17 ¼ 26% (46 cells, FISH)
Blood: 46,XY
Skin ﬁbroblasts: T17 ¼ 60%
(10 cells)
Buccal smear: T17 ¼ 0%
(FISH)
Urinary sediment:
T17 ¼ 66% (53 cells) (FISH)
No UPD 17, paternal origin
of T17
Delivery at 33 wk, 1010 g,
growth delay, facial
dysmorphism, gut
malrotation, duodenal
atresia, hypoplasia of
cerebellar vermis, inguinal
hernia, aortic valve
stenosis, hemihypoplasia of
left leg, mental retardation
at age 9 y
Witters et al [22]
Witters & Fryns [23]
47,XY,þ17/46,XY Abnormal ultrasound:
pleural effusion,
ventriculomegaly
T17 ¼ 50% (cultured cells)
T17 ¼ 13% (100 cells, FISH)
Cord blood: T17 ¼ 0%
Placenta: T17 ¼ 0%
(50 cells)
Cord: T17 ¼ 0.5% (50 cells)
Peripheral blood: T17 ¼ 0%
Urine: T17¼ 16% (100 cells)
Buccal cells: T17 ¼ 4%
(100 cells)
No UPD 17
Resolution of pleural
effusion at 24 wk, delivery
at 39 wk, 2905 g, large
fontanelle, mild facial
asymmetry, right hearing
loss, mild dysmorphic
features, postural
hypotonia & limited speech
at 18 mo, no major
developmental problems at
age 3 y
Daber et al [24]
Case 1 47,XX,þ17/46,XX Abnormal ultrasound: short
long bones, facial dysmorphism,
hypoplastic inferior vermis,
absent right fourth sacral vertebra
& right kidney, single ventricle &
truncus arteriosus
T17 ¼ 100% (15 colonies) Peripheral blood: T17 ¼ 0%
Buccal mucosa: T17 ¼ 0%
(BAC array)
Right skin: T17 ¼ 75% (SNP
array)
Left skin: T17 ¼ 50% (SNP
array)
Abnormal live-born,
delivery at 36 wk, minor
anomalies, CHD,
asymmetry, intestinal
malrotation, death at 9 d
Case 2 47,XY,þ17/46,XY Abnormal ultrasound: TOF T17 ¼ 23.6% (17 colonies) Buccal mucosa: T17 ¼ 0%
(SNP array)
Peripheral blood: T17 ¼ 0%
(SNP array)
Skin: T17 ¼ 0% (SNP array)
Abnormal live-born;
ventriculomegaly,
hydrocephalus, TOF,
normal psychomotor
development & mild
speech delay at age 1 y
(continued on next page)
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Authors Cases Indication Amniocentesis Conﬁrmatory studies Outcome & phenotype
de Vries et al [25] 47,XX,þ17/46,XX Abnormal ultrasound: single
umbilical artery, echogenic
cardiac foci, symmetric short
long bones
T17 ¼ 95% (19 clones)
T17 ¼ 93% (45 clones, FISH)
Amnion: T17 ¼ 43%
(100 cells) (FISH)
Placenta: T17 ¼ 33%
(100 cells) (FISH)
Cord: T17 ¼ 60% (100 cells)
(FISH)
Cord blood: T17 ¼ 1%
(100 cells) (FISH)
Skin (right buttock):
T17¼ 55% (100 cells) (FISH)
Skin (left buttock):
T17¼ 44% (100 cells) (FISH)
Skin (right shoulder):
T17¼ 45% (100 cells) (FISH)
Cultured amniocytes:
T17 ¼ 75-90% (SNP array)
Maternal origin of T17
Additional abnormal
ultrasound of distal defect
of cerebellar vermis,
thickened right ventricle, a
small left ventricle,
pericardial effusion, TOP,
facial dysmorphism
Baltensperger
et al [26]
47,XY,þ17/46,XY Abnormal ultrasound:
cystic hygroma, short long
bones, pleural effusion, cerebellar
cyst, VSD
T17 ¼ 37% (microarray) Skin (foreskin): T17 ¼ 75%
(20 cells)
Abnormal live-born,
delivery at 35 wk, 2280 g;
facial dysmorphism,
postaxial polydactyly of
right foot, growth
retardation, cerebellar
vermian hypoplasia, mild
cerebellar hemisphere &
pons hypoplasia, food
deformity, VSD, pulmonary
hypertension,
cardiomyopathy, moderate
hearing loss,
developmental delay at age
14 mo
Present case 47,XX,þ17/46,XX AMA T17 ¼ 19% (21 colonies)
Retap:
T17 ¼ 0% (17 colonies)
Cord blood: T17 ¼ 0%
(40 cells)
Retap:
Uncultured amniocytes:
T17 ¼ 4.7% (105 cells)
(FISH)
aCGH: no genomic
imbalance, no UPD 17
Urinary cells:
T17 ¼ 5.6% (90 cells) (FISH)
Normal live-born, delivery
at 38 wk, 2748 g, normal at
age 11 mo
aCGH ¼ array comparative genomic hybridization; AMA ¼ advanced maternal age; BAC ¼ bacterial artiﬁcial chromosome; CHD ¼ congenital heart defects; CVS ¼ chorionic
villus sampling; FISH ¼ ﬂuorescence in situ hybridization; IUGR ¼ intrauterine growth restriction; LTC ¼ long-term culture; MSAFP ¼ maternal serum a-fetoprotein;
SNP ¼ single nucleotide polymorphism; STC ¼ short-term culture; T17 ¼ trisomy 17; TOF ¼ tetralogy of Fallot; TOP ¼ termination of pregnancy; UPD ¼ uniparental disomy;
VSD ¼ ventricular septal defect; d ¼ not available; () ¼ total number.
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with severemalformations. Shaffer et al [28] reported an 8-year-old
male with mosaic trisomy 17 and the clinical features of mental
retardation, seizures, attention deﬁcit hyperactivity, autistic disor-
ders, hearing loss, growth retardation, microcephaly, and minor
anomalies. In the case reported by Shaffer et al [28], although the
peripheral blood lymphocyte chromosomes were normal, the tri-
somy 17 cell lines in skin biopsy increased from 18% at age 3 years
to 80% at age 8 years. In this regard, Hsu et al [13] suggested that
mosaic trisomy 17 at amniocentesis should not be taken lightly, and
Utermann et al [21] suggested that the clinical signiﬁcance of
mosaic trisomy 17 at amniocentesis remains uncertain. To prove
the optimistic fetal outcome estimation in cases of mosaic trisomy
17 at amniocentesis with normal prenatal ultrasound and a low
mosaicism level, more clinical reports with long-term observations
will be required.
In summary, we present prenatal diagnosis and molecular cy-
togenetic analysis of mosaic trisomy 17 using uncultured and
cultured amniocytes in a pregnancy with a favorable fetal outcome.
We demonstrate the usefulness of analyses of uncultured amnio-
cytes by interphase FISH and aCGH for rapid conﬁrmation of low-
level trisomy 17 mosaicism at amniocentesis, and by QF-PCR forrapid exclusion of UPD 17. A review of the literature shows a cor-
relation between an adverse fetal outcome and a higher trisomy 17
mosaicism level at amniocentesis associated with ultrasound
abnormality.Conﬂicts of interest
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